Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-024 in recurrent or metastatic TNBC
NCT07281976Phase 2Recruiting
- Sponsor
- Leads Biolabs
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of opamtistomig in triple-negative breast cancer (TNBC), sponsored by Leads Biolabs. Started Jan 2026; status: recruiting.
02
Drugs
opamtistomig
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07281976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281976.